-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
China Pharmaceutical News 2026 Spring Festival Grassroots Visit | Greening the API Production Line
Category:
TIME：2026-02-19
On February 9, the day before Northern China’s “Little New Year,” around 4 p.m., the caffeine API production line at Hebei Guangxiang Pharmaceutical Co., Ltd. (hereinafter referred to as Guangxiang Pharmaceutical) was bustling with activity.
Guangxiang Pharmaceutical boasts substantial exports of caffeine API, a trend that is steadily growing. “In 2025, our caffeine exports are expected to reach approximately 5,000 metric tons—more than double the level two years ago—and we anticipate a further 20% increase this year,” said Zhu Shujie, Chairman of Guangxiang Pharmaceutical. The company currently supplies about 20% of the global demand for caffeine API, with 80% of its output destined for export, primarily to Europe, Japan, and other regions.
Speaking about the increase in export volumes, Zhu Shujie’s eyes lit up and his pace of speech quickened almost unconsciously: “In 2024, we obtained carbon-footprint certification from the South German Group, and in 2025 we secured the European Pharmacopoeia Compliance Certificate. Moreover, by adopting greener and more efficient production technologies, we have further expanded our presence in the European market.”
The “green and efficient production technology” mentioned by Zhu Shujie refers to a biofilm technology independently developed over two years by Guangxiang Pharmaceutical. In 2025, the company’s three caffeine production lines all successfully replaced traditional evaporation techniques with this technology.
Zhu Shujie himself was involved in the R&D of this biomembrane technology. He explained that, in the past, the production of caffeine APIs required evaporation to separate the active ingredients from impurities in the mother liquor; in contrast, this biomembrane technology acts like a “filter,” selectively “blocking” large-molecule impurities while allowing the active ingredients to pass through.
A major advantage of this technology is its ability to reduce wastewater generation, thereby achieving emission reduction at the source.
“In the past, producing one ton of caffeine generated roughly 200 cubic meters of wastewater; thanks to the application of this technology, that figure has now dropped to about 50 cubic meters,” Zhu Shujie said proudly.
When asked about the rationale for developing green manufacturing processes, Zhu Shujie candidly acknowledged that it is closely tied to demand in both domestic and international markets. “International markets, particularly Europe, are steadily tightening carbon-emission standards for products,” he said. “Products manufactured using low-carbon processes are therefore more competitive in the global marketplace.”
In fact, green manufacturing, as a critical issue for API manufacturers, is of widespread concern across the industry, and large-scale API exhibitions invariably feature dedicated seminars and networking sessions focused on this topic.
There is a two-way alignment between policy initiatives and industry efforts. In 2020, the Ministry of Industry and Information Technology and three other departments issued the “Guiding Opinions on Promoting Green Development of the Active Pharmaceutical Ingredient Industry”; in 2021, the National Development and Reform Commission and the Ministry of Industry and Information Technology released the “Notice on Implementing the Plan for High-Quality Development of the Active Pharmaceutical Ingredient Industry”; and in the same year, nine government departments jointly issued the “Notice on Issuing the 14th Five-Year Plan for the Development of the Pharmaceutical Industry.” These successive policy measures have continuously guided API companies toward a green transformation, making green development an essential component of their high-quality growth.
Policy guidance has been progressively refined, prompting more proactive corporate transformation. An increasing number of API manufacturers are incorporating green production into their development plans. Across the country, the cohort of “green model” enterprises is steadily expanding. According to data released by the Ministry of Industry and Information Technology, over the past three years, each year at least 10 API companies have been recognized as green factories.
Green development requires sustained, long-term effort.
Currently, Guangxiang Pharmaceutical’s biomembrane technology is being extended to production lines for theophylline, aminophylline, and other products. As the Spring Festival approaches, Zhu Shujie has once again immersed himself in the laboratory, diligently working to further expand the application of this technology across more production lines.
A new green journey has already begun unfolding beneath our feet.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
